E
BCLI

Ergoteles’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Ergoteles’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,178
Closed -$405K – 1242
2021
Q3 		$405K Sell
8,178
-111
-1% -$5.84K 0.01% 673
2021
Q2 		$472K Buy
+8,289
New +$443K 0.01% 840
2021
Q1 		– Sell
-1,440
Closed -$98K – 805
2020
Q4 		$98K Buy
+1,440
New +$196K ﹤0.01% 628

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's BCLI Position: Q4 2021 in Review

Ergoteles sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2021, closing a stake of 8,178 shares — an estimated $405K sold.

Ergoteles first reported a position in BCLI in Q4 2020 and held it in 3 quarters. The position peaked at $472K in Q2 2021. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2021.

  • Ergoteles reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 8,178 BRAINSTORM CELL THERAPUTC shares in Q4 2021, an estimated $405K.
  • Ergoteles first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 3 quarters.
  • Ergoteles's BRAINSTORM CELL THERAPUTC position peaked at $472K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.